Category: Featured

22 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed an agreement with The Sheba Fund for Health Services and Research, Chaim Sheba Medical Center to commence a Phase 1b/2 trial in relapsed/refractory Acute Myeloid…

Race Oncology presented to the MST Access Australian Micro & Small Caps Conference 2021 on the 17th June 2021.

Contract signed to support Race’s Phase 2 relapsed/refractory Acute Myeloid Leukemia (AML) trial at the Chaim Sheba Medical Center in Israel Trialog Clinical Trials Ltd to supply trial drugs and provide other clinical services Clinical trial contract is in final…

Race CEO/MD Phillip Lynch speaks to the Australia Shareholders Association about Race Oncology and our Three Pillar strategy to commercialise Bisantrene.

Contract Research Organisation Parexel has been appointed to support an Australian trial of Bisantrene in Acute Myeloid Leukemia (AML) patients with extramedullary disease The study led by Associate Professor Anoop Enjeti will underpin future Phase 2/3 trials in the USA…

20 May 2021 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Professor Michael Kelso as Principal Scientist. Prof Kelso will be responsible for providing scientific leadership, developing, managing, and implementing Race’s preclinical and clinical research programs…

Race Oncology updates our shareholders on our progress and clinical plans for 2021 and beyond.

Race Oncology Limited (“Race”) is pleased to announce a team of researchers, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MD Anderson Cancer Center (Texas, USA), have identified a number of clinically translatable drug combinations that…

Race Oncology Limited (ASX: RAC) is pleased to announce that it has received binding commitments to raise $5.4m (before associated costs) in an oversubscribed equity placement to new and existing institutional and sophisticated investors (Placement), and the commencement of a…

Race Oncology Limited (ASX: RAC) (Race) is pleased to release an updatedinvestor presentation and invite investors to join a special online investor briefing. Updated Presentation An update on the Company’s Three Pillar strategy and recent related highlights Updates to the…